ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2020

Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase

Peter Lipsky1 and anthony yeo2, 1AMPEL BioSolutions, Charlottesville, VA, 2Independent consultant, Ann arbor, MI

Meeting: ACR Convergence 2024

Keywords: clinical trial, gout, hyperuricemia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Pegloticase is a pegylated recombinant uricase approved for treatment of chronic uncontrolled gout. Because of the development of anti-drug antibodies (ADA), persistent urate lowering responsiveness is limited to approximately 42% of patients. Factors contributing to the lack of responsiveness have not been identified, however, making it difficult to predict individuals likely to be persistent responders.

Methods: A total of 225 subjects from the phase 3 trials of pegloticase in chronic uncontrolled gout were  analyzed1. Unresponsiveness was defined as failure to have a serum urate < 6 mg/dL during 80% of the measurements after 6 months of treatment. For this analysis, plasma urate (PUA) was employed to avoid artifact related to the presence of active pegloticase in blood samples. Logistic regression and propensity models with response and non-response as the classes were developed using the following variables: gender, age, baseline BMI, weight (kg), diabetic status, presence of tophi, ever used methylprednisolone, Fib-4, creatinine,  PUA and pegloticase levels.

Results: First, we developed a logistic regression model based on information assessed 24 hours after the initial dose of pegloticase to avoid the effect of ADA that usually develops later in treatment 2. Of all the variables, logistic modelling indicated that baseline weight (p = 0.0133) and 24 hr PUA (p = 0.0008) were significantly related to persistent responsiveness. Relating 24 hr PUA to the propensity score yielded a significant (p < 0.0001) relationship: Propensity score = 0.43733 -0.04970* PUA indicating that lower 24 hr PUA is associated with persistent response (Figure 1). Because monitoring of pegloticase treatment usually occurs 2 weeks after initial treatment, we also generated a logistic regression model employing data obtained at this time. The logistic regression model using the data at 2 weeks post initial pegloticase treatment showed that only PUA ( p< 0.0001) was significant. The relationship between 2 week PUA to the propensity score is described by Propensity score = 0.53161 -0.04995*PUA (p< 0.0001), indicating that lower PUA values are associated with persistent response (Figure 2).

Conclusion: Measurement of PUA at 24 hours and 2 weeks post initial treatment provides information that can predict persistent urate lowering in patients with chronic uncontrolled gout. Weight is associated with  24 hr PUA levels, suggesting that weigh-based dosing could be useful to increase responsiveness to pegloticase.

Supporting image 1

Supporting image 2


Disclosures: P. Lipsky: None; a. yeo: None.

To cite this abstract in AMA style:

Lipsky P, yeo a. Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prediction-of-the-response-of-patients-with-chronic-uncontrolled-gout-to-pegloticase/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prediction-of-the-response-of-patients-with-chronic-uncontrolled-gout-to-pegloticase/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology